📊 SPRB Key Takeaways
Is Spruce Biosciences, Inc.. (SPRB) a Good Investment?
Spruce Biosciences is a pre-commercial stage biopharmaceutical company with zero revenue and annual cash burn of $33.3M, leaving approximately 1.5 years of runway with current cash position of $48.9M. While the balance sheet is debt-free with strong liquidity ratios, the company's fundamental viability depends entirely on successful drug development and clinical trials with significant execution risk and no near-term revenue visibility.
Why Buy Spruce Biosciences, Inc.. Stock? SPRB Key Strengths
- Zero long-term debt with strong balance sheet discipline
- Excellent liquidity position (5.17x current ratio) with $48.9M cash reserves
- Improving operational efficiency (net loss decreased 26.5% YoY, EPS improved 47.3% YoY despite pre-revenue stage)
SPRB Stock Risks: Spruce Biosciences, Inc.. Investment Risks
- Complete revenue absence (-100% YoY) with no established commercial product
- Significant annual cash burn of $33.3M creates limited runway (~18 months at current burn rate)
- High biotech execution risk dependent on clinical trial success, FDA approvals, and regulatory outcomes with substantial failure probability
- Negative profitability metrics (ROE -91.7%, ROA -73.5%) with no clear path to profitability without successful commercialization
- Will require capital raises or milestone achievements to avoid cash exhaustion
Key Metrics to Watch
- Monthly cash burn rate and runway extension (critical for survival timeline)
- Clinical trial progression and FDA regulatory milestone achievements
- Future capital raise announcements and dilution impact on equity
- Operating cash flow trend (indicates cost structure management)
- Drug pipeline advancement and commercial readiness metrics
Spruce Biosciences, Inc.. (SPRB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.17x current ratio provides a solid financial cushion.
SPRB Profit Margin, ROE & Profitability Analysis
SPRB vs Healthcare Sector: How Spruce Biosciences, Inc.. Compares
How Spruce Biosciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Spruce Biosciences, Inc.. Stock Overvalued? SPRB Valuation Analysis 2026
Based on fundamental analysis, Spruce Biosciences, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Spruce Biosciences, Inc.. Balance Sheet: SPRB Debt, Cash & Liquidity
SPRB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Spruce Biosciences, Inc..'s revenue has declined by 51% over the 5-year period, indicating business contraction. The most recent EPS of $-96.40 indicates the company is currently unprofitable.
SPRB Revenue Growth, EPS Growth & YoY Performance
SPRB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$8.2M | $-14.58 |
| Q2 2025 | N/A | -$2.1M | $-3.50 |
| Q1 2025 | N/A | -$11.6M | $-0.28 |
| Q3 2024 | $602.0K | -$8.7M | $-0.21 |
| Q2 2024 | $1.6M | -$9.2M | $-0.22 |
| Q1 2024 | $2.0M | -$11.6M | $-0.28 |
| Q3 2023 | N/A | -$11.4M | $-0.30 |
| Q2 2023 | N/A | -$11.9M | $-0.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Spruce Biosciences, Inc.. Dividends, Buybacks & Capital Allocation
SPRB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Spruce Biosciences, Inc.. (CIK: 0001683553)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SPRB
What is the AI rating for SPRB?
Spruce Biosciences, Inc.. (SPRB) has an AI rating of SELL with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SPRB's key strengths?
Claude: Zero long-term debt with strong balance sheet discipline. Excellent liquidity position (5.17x current ratio) with $48.9M cash reserves.
What are the risks of investing in SPRB?
Claude: Complete revenue absence (-100% YoY) with no established commercial product. Significant annual cash burn of $33.3M creates limited runway (~18 months at current burn rate).
What is SPRB's revenue and growth?
Spruce Biosciences, Inc.. reported revenue of $0.0.
Does SPRB pay dividends?
Spruce Biosciences, Inc.. does not currently pay dividends.
Where can I find SPRB SEC filings?
Official SEC filings for Spruce Biosciences, Inc.. (CIK: 0001683553) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SPRB's EPS?
Spruce Biosciences, Inc.. has a diluted EPS of $-50.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SPRB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Spruce Biosciences, Inc.. has a SELL rating with 65% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SPRB stock overvalued or undervalued?
Valuation metrics for SPRB: ROE of -91.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SPRB stock in 2026?
Our dual AI analysis gives Spruce Biosciences, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SPRB's free cash flow?
Spruce Biosciences, Inc..'s operating cash flow is $-33.3M, with capital expenditures of $0.0.
How does SPRB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -91.7% (avg: 15%), current ratio 5.17 (avg: 2).